Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcos García Aguado

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
International Journal of Cardiology|January 20, 2004
Delayed myocardial perforation following pacemaker implantationVicente Barriales Alvarez, José A Alvarez Tamargo, Marcos García Aguado, et al.
Medicina Clinica|October 19, 2002
[Floating thrombi on the eustachian valve as complication of venous thromboembolic disease]Vicente Barriales Alvarez, José A Alvarez Tamargo, Marcos García Aguado, et al.
Medicina Clinica|November 28, 2002
[Cardiac tamponade secondary to hemorrhagic pericarditis following thrombolysis for acute myocardial infarction]Vicente Barriales Alvarez, José Antonio Alvarez Tamargo, Marcos García Aguado, et al.
International Journal of Cardiology|May 28, 2003
Left intraventricular pressure gradient induced by cardiac tamponade after thrombolysis for acute myocardial infarctionVicente Barriales Alvarez, José A Alvarez Tamargo, Marcos García Aguado, et al.
Revista Espanola De Cardiologia (English Ed.)|May 21, 2016
The Importance of Family-genetic Screening: The Phenotype Caused by the p.L3778F Ryanodine Receptor Mutation is Likely Less Severe Than Previously ThoughtMaría Del Val Groba-Marco, Fernando Benito-Bartolomé, Marcos García-Aguado, et al.
Revista Espanola De Geriatria Y Gerontologia|January 2, 2020
Sacubitril/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohortAlberto Esteban-Fernández, Pablo Díez-Villanueva, Lourdes Vicent, et al.
Cardiology|April 19, 2019
Sex Influence on the Efficacy and Safety of Sacubitril/ValsartanLourdes Vicent, Ana Ayesta, Alberto Esteban-Fernández, et al.
Journal of Cardiovascular Pharmacology|December 13, 2018
Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective RegistryLourdes Vicent, Alberto Esteban-Fernández, Manuel Gómez-Bueno, et al.
Journal of Cardiovascular Pharmacology|June 8, 2018
Clinical Profile of a Nonselected Population Treated With Sacubitril/Valsartan Is Different From PARADIGM-HF TrialLourdes Vicent, Alberto Esteban-Fernández, Manuel Gómez-Bueno, et al.
Cardiology|January 16, 2020
Left Ventricular Ejection Fraction Recovery in Patients with Heart Failure and Reduced Ejection Fraction Treated with Sacubitril/ValsartanPablo Díez-Villanueva, Lourdes Vicent, Francisco de la Cuerda, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
International Journal of Cardiology|January 20, 2004
Delayed myocardial perforation following pacemaker implantationVicente Barriales Alvarez, José A Alvarez Tamargo, Marcos García Aguado, et al.
Medicina Clinica|October 19, 2002
[Floating thrombi on the eustachian valve as complication of venous thromboembolic disease]Vicente Barriales Alvarez, José A Alvarez Tamargo, Marcos García Aguado, et al.
Medicina Clinica|November 28, 2002
[Cardiac tamponade secondary to hemorrhagic pericarditis following thrombolysis for acute myocardial infarction]Vicente Barriales Alvarez, José Antonio Alvarez Tamargo, Marcos García Aguado, et al.
International Journal of Cardiology|May 28, 2003
Left intraventricular pressure gradient induced by cardiac tamponade after thrombolysis for acute myocardial infarctionVicente Barriales Alvarez, José A Alvarez Tamargo, Marcos García Aguado, et al.
Revista Espanola De Cardiologia (English Ed.)|May 21, 2016
The Importance of Family-genetic Screening: The Phenotype Caused by the p.L3778F Ryanodine Receptor Mutation is Likely Less Severe Than Previously ThoughtMaría Del Val Groba-Marco, Fernando Benito-Bartolomé, Marcos García-Aguado, et al.
Revista Espanola De Geriatria Y Gerontologia|January 2, 2020
Sacubitril/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohortAlberto Esteban-Fernández, Pablo Díez-Villanueva, Lourdes Vicent, et al.
Cardiology|April 19, 2019
Sex Influence on the Efficacy and Safety of Sacubitril/ValsartanLourdes Vicent, Ana Ayesta, Alberto Esteban-Fernández, et al.
Journal of Cardiovascular Pharmacology|December 13, 2018
Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective RegistryLourdes Vicent, Alberto Esteban-Fernández, Manuel Gómez-Bueno, et al.
Journal of Cardiovascular Pharmacology|June 8, 2018
Clinical Profile of a Nonselected Population Treated With Sacubitril/Valsartan Is Different From PARADIGM-HF TrialLourdes Vicent, Alberto Esteban-Fernández, Manuel Gómez-Bueno, et al.
Cardiology|January 16, 2020
Left Ventricular Ejection Fraction Recovery in Patients with Heart Failure and Reduced Ejection Fraction Treated with Sacubitril/ValsartanPablo Díez-Villanueva, Lourdes Vicent, Francisco de la Cuerda, et al.
Pageof 3